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CXCR4 is a target of growing interest for the development of new therapeutic drugs and 
imaging agents as its role in multiple disease states has been demonstrated. AMD3100, a 
CXCR4 chemokine receptor antagonist that is in current clinical use as a haematopoietic stem 
cell mobilising drug, has been widely studied for its anti-HIV properties, potential to inhibit 
metastatic spread of certain cancers and, more recently, its ability to chelate radiometals for 
nuclear imaging. In this study, AMD3100 is functionalised on the phenyl moiety to 
investigate the influence of the structural modification on the anti-HIV-1 properties and 
receptor affinity in competition with anti-CXCR4 monoclonal antibodies and the natural 
ligand for CXCR4, CXCL12. The effect of complexation of nickel(II) in the cyclam cavities 
has been investigated. Two amino derivatives were obtained and are suitable intermediates 
for conjugation reactions to obtain CXCR4 molecular imaging agents. A fluorescent probe 
(BODIPY) and a precursor for 18F (positron emitting isotope) radiolabelling were conjugated 
to validate this route to new CXCR4 imaging agents. 
 Introduction 
The CXCR4 chemokine receptor is a seven transmembrane helix protein, and member of the 
G-protein-coupled receptor (GPCR) superfamily.1 It has only one naturally occurring 
endogenous ligand known as SDF-1 or CXCL12.2 Together with its natural ligand, CXCR4 is 
a central part of the signalling system in the human body that results in a variety of normal 
physiological responses, such as chemotaxis, cell survival and proliferation, intracellular 
calcium flux, and gene transcription. However CXCR4 is also involved in the pathogeneses 
of a wide range of diseases.3 Malignant cells from at least 23 different types of cancer express 
the chemokine receptor CXCR4 and respond to its ligand CXCL12.4 Furthermore, CXCR4 is 
a co-receptor for T-cell tropic strains of human immunodeficiency virus-1 (HIV-1) and 
allows fusion and entry of the virus into human white blood cells.5 Hence, CXCR4 is a target 
of growing interest for the development of anti-HIV drugs and in the field of diagnostic 
oncology. Clinically AMD3100 is used in combination with G-CSF (granulocyte colony 
stimulating factor) to mobilise haematopoietic stem cells and allow harvesting.  
Inhibition of the CXCR4-CXCL12 signalling was investigated as a therapeutic strategy 
using antagonists of the natural ligand. Several CXCR4-binding agents, including antibodies 
and peptide-based antagonists have been developed.6 In the search for new anti-HIV agents, 
bicyclam compounds were discovered as CXCR4 antagonists with potent and selective anti-
HIV activities.7 These molecules consist of two 14-member tetraaza macrocyclic rings, linked 
either by an aliphatic bridge or an aromatic bridge such as AMD3100. The latter, unlike 
many other existing HIV drugs that target the virus after it has infected a healthy cell, blocks 
the virus from entering the cell, inhibiting the replication of both HIV-1 and HIV-2.8 
AMD3100 binds to the CXCR4 chemokine receptor mainly via electrostatic interaction 
between the positively charged protonated amino nitrogens of the cyclam moieties and the 
negatively charged carboxylates of the aspartate and glutamate residues of the receptor.9 
AMD3100 has also been demonstrated to be a ligand for another chemokine receptor, 
CXCR7. In contrast to its antagonistic effect blocking the CXCR4/CXCL12 interaction, 
AMD3100 positively modulates CXCL12 effects on binding to CXCR7, it is therefore 
qualified as an allosteric agonist of CXCR7.10 AMD3100 was clinically tested as an anti-HIV 
drug but the trial was discontinued in favour of an orally available CXCR4 antagonist.11 
Nevertheless, AMD3100 demonstrated a great potential in hematopoietic stem cell 
mobilisation and is now approved by the U.S. Food and Drug Administration for use in non-
Hodgkin's lymphoma and multiple myeloma patients.12 
With the aim of optimising the anti-HIV activity of bis-azamacrocycles, many parameters 
of AMD3100 have been studied to determine the modifications that can be tolerated whilst 
maintaining high CXCR4 receptor affinity. Analogues were synthesised either with a 
different linker, a macrocycle ring size varying from 12 to 16 ring members,13 the 
introduction of one or more heteroatoms in the macrocycle ring or replacement of one amino 
group by a heteroaromatic, all analogues resulting in a reduced anti-HIV potency (Fig. 1).14 
 
 
 
Fig. 1 AMD3100 and derivatives studied for 
their anti-HIV activities and CXCR4 
affinities. 
 
Because of the preorganisation and the flexibility of their macrocyclic framework, 
macrocyclic polyamines such as cyclam, are known to bind to metal ions and form highly 
stable metal complexes. Complexes of AMD3100 with metal cations were prepared and the 
incorporation of ZnII, NiII and CuII led to the enhancement of the binding affinity to CXCR4 
receptor and a higher anti-HIV activity in most cases. The nickel(II) complex of AMD3100 
in solution can adopt the folded (cis-V) and planar (trans-III) configuration, rearranging to 
give the cis-V compound on binding to the protein aspartate residues.15 Studies with 
AMD3100 analogues complexes with configurationally restricted macrocycles, where ethyl 
bridges link adjacent and non-adjacent nitrogen atoms to give respectively side and cross 
bridged cyclams, demonstrated that the rigidification of the cyclic scaffold may be a route 
toward the optimisation of the interactions of the antagonist with the receptor.16 Additionally, 
as metal ion incorporation was shown to enhance the affinity of AMD3100 for its receptor, 
the ligand was used for direct radiolabelling with 62Zn, 64Cu, 67Ga and 99mTc, resulting in 
tracers suitable for positron emission tomography (PET) and single-photon emission 
computed tomography (SPECT) to image CXCR4 expression in human cancer xenografts in 
mice.17 
Only two examples of optical CXCR4 imaging agents based on cyclam structures have 
been studied despite the advantages of optical imaging. A rhodamine conjugated to a 
reinforced cyclam competes with anti-CXCR4 antibodies during binding competition when 
labelled with copper(II)18 and a fluorescent AMD3100 analogue with an anthracenyl moiety 
used as a spacer shows a significant reduction of the affinity probably due to the lipophilic 
character of the anthracenyl group.19 
In this study, new CXCR4 antagonists are investigated as potent anti-HIV agents and 
platforms for conjugation in molecular imaging agent design. The syntheses of new 
AMD3100 analogues functionalised on the phenyl moiety by an ester or an ethylenediamine 
moiety are discussed and we report the influence of the functionalisation on the affinity 
towards the CXCR4 chemokine receptor and antiviral potency against an X4 HIV-1 strain. 
Metal complex formation with nickel(II) and the influence on the binding and antiviral 
potency will also be presented. Ni2+ was chosen because its incorporation in the biscyclam 
AMD3100 enhances the binding to the chemokine receptor CXCR4 by 50-fold. This is the 
highest affinity obtained by incorporation of a transition metal.22 Finally, the functionalisation 
on the phenyl spacer allowed the introduction of an imaging component, i.e. optical probe or 
PET imaging agent precursor, confirming the versatility of the modified AMD3100 
derivatives. 
Results and discussion 
Synthetic procedures 
Several synthetic routes to produce AMD3100 are reported in the literature.20 A cyclam ring 
protected with tosyl, mesityl, diethylphosphoramidate (Dep) or tert-butoxycarbonyle (Boc) 
groups is used as a starting material. Indeed, the best synthetic approach for bridging two 
macrocyclic units is to use a triprotected tetraazamacrocycle, in order to avoid the formation 
of polymers. Boc protecting groups were chosen as they can be easily removed by acidic 
treatment. The reaction of the protected macrocycle with α,α-dibromo-p-xylene and the 
deprotection in acidic conditions give access to AMD3100 in two steps (Scheme 1).  
 
 
Scheme 1 General synthesis of AMD3100. 
 
To investigate the influence of a functionalisation of the phenyl moiety on AMD3100 
properties, we considered the synthesis of a p-dibromoxylyl spacer substituted with an ester 
group. The precursor is obtained in two steps (Scheme 2) starting from a commercially 
available product, 2,5-dimethylbenzoic acid.21 Esterification with methanol using sulfuric acid 
as a catalyst yields compound 1 in 92% yield. 2 is then prepared through NBS-based bis-
bromination of the aryl methyl groups of 1. 
 
 
 
Scheme 2 Synthesis of a dibromo aromatic 
spacer bearing an ester group.  
AMD3100 derivative 3 is obtained in 82% yield, after condensation of two equivalents of 
tris(Boc)cyclam on compound 2 in the presence of a base (Scheme 3). Nucleophilic attack of 
ethylenediamine on the ester function gives access to 4 after 6 days at 60 °C. Compounds 3 
and 4 are then deprotected in acidic condition to form respectively 5 and 6 in good yields. 
 
  
Scheme 3 Synthesis of new AMD3100 
analogues functionalised with an ester and an 
ethylenediamine group. 
 
As it has been shown that the incorporation of Ni2+ in the biscyclam AMD3100 enhances 
the binding to the chemokine receptor by 50-fold,22 we investigated the metal complex 
formation of our analogues. Additionally, Ni2+-cyclam complexes are known to be 
particularly inert due to their stability constants (log K) indicative of high thermodynamic 
stability (19.9–20.3)23 and their slow kinetics of dissociation.24 The complexes persist almost 
indefinitely even in strong acidic solutions and the only reported method to remove Ni2+ from 
cyclam involves cyanide at high temperature. 
Thus, after deprotonation of 5 and 6 with NaOH (16 M) and extraction with chloroform, 
two equivalents of Ni(NO3)2·6H2O were added to obtain the corresponding Ni2+ complexes 
(Scheme 4). Purification by reverse phase chromatography to remove any trace of free 
nickel(II) was performed to obtain 7 and 8 in 18% and 39% yield respectively. Yields are low 
in these cases due to the purification process. In order to investigate if ethylenediamine 
pendant arm coordinates one of the nickel atoms in compound 8, UV-Visible absorption 
spectra was recorded in PBS at room temperature (see ESI†). The latter shows a band at 460 
cm−1, characteristic of a low-spin NiII tetramine complex. The amino pendant arm is therefore 
not involved in the coordination sphere of nickel.25 
 
  
Scheme 4 Nickel(II) complex formation of 
the AMD3100 analogues.  
Biological assays: antibody competition, calcium signalling and anti-HIV 
activity 
Cellular binding assays of our AMD3100 analogues to the CXCR4 receptor were 
investigated in a competition assay with an anti-CXCR4 monoclonal antibody (mAb) (12G5 
conjugated to Phycoerythrin). A T-lymphocyte cell line (Jurkat) that expresses high levels of 
the CXCR4 receptor was used and the binding of compounds 5, 6, 7 and 8 to the cells are 
analysed by flow cytometry. The binding assay is carried out by saturation of the cells’ 
receptors with a high concentration of analogues (ca. 20 μM). After incubating with a 
saturating concentration of the antagonist, cells are washed to remove the excess of unbound 
compound and the specific fluorescent antibody is introduced. After a second incubation, 
cells are washed to remove the excess of antibody and compound displaced by the antibody. 
Then, cells are analysed by flow cytometry. The Mean Fluorescent Intensity (MFI) is used as 
a measure of binding and a quantitative way of calculating the inhibition percentage of mAb 
binding. AMD3100 is used as a reference compound. The non-metallated ligands 5 and 6 
both show a significant decrease in the inhibition percentage compared to AMD3100 with 
45% and 46% respectively (Table 1) (Fig. 2). Incorporation of a metal ion into the 
macrocyclic rings of AMD3100 analogues increases binding affinity to CXCR4, complexes 7 
and 8 show higher inhibition percentages, 73% and 84% respectively, than the non-
metallated ligands (Table 1) (Fig. 2). This is in agreement with Bridger and co-workers 
studies.22 A mutational analysis of the CXCR4 binding site for AMD3100 has identified 
amino acid Asp171 and Asp262 as key residues involved in the binding to the CXCR4 receptor.11 
The carboxylate groups of the receptor residues form three (one strong, one intermediate and 
one weak) hydrogen bonds with protonated cyclam of AMD3100. It was later determined 
that the increased binding affinity of the metal ion substituted AMD3100 is obtained through 
enhanced interaction of one of the cyclam ring systems with carboxylate group of Asp262.22 
With metal complexes, coordination of the carboxylate oxygens to the metal centre can occur 
while one weaker hydrogen bond to a nitrogen atom in the cyclam ring remains. Coordination 
interactions are stronger interactions than hydrogen bonding. Hence they are thought to be the 
dominant interactions for metal complexes. Complexes 7 and 8 should have stronger 
interactions with the CXCR4 receptor as aspartate residue coordinates nickel(II), resulting in 
higher inhibition percentages compared to their unmetalated ligands 5 and 6. Even if the 
functionalisation of our AMD3100 analogues disrupted the affinity towards CXCR4, the 
incorporation of nickel(II) in the cyclam cavities has a positive effect resulting in inhibition 
percentages close to those observed for the reference compound AMD3100. If we compare 
the different functionalisations of the complexes 7 and 8, the ethylenediamine analogue has a 
slightly higher inhibition percentage, which may be due to more flexible pendant arm that can 
form hydrogen bonds more easily.  
 
 
Fig. 2 Flow cytometric histogram plots for the 
binding of 12G5 mAb in competition with 
compound 5 (light green) and 6 (dark green) 
(A) and with compounds 7 (light blue) and 8 
(dark blue) (B). Negative control (purple), 
positive control (red) and binding of 12G5 
mAb in competition with AMD3100 (orange) 
are shown. 
 
Table 1 Inhibition of anti-CXCR4 mAb (clone 12G5) binding to CXCR4+ jurkat cells  
Compound Control MFIa Inhibition percentage 
Compound Control MFIa Inhibition percentage 
a Mean fluorescent intensity used to calculate the amount of antibody bound to CXCR4.  
 Negative 344.67  
5   708.57 45% 
6   704.29 46% 
7   524.78 73% 
8   451.59 84% 
AMD3100  413.90 90% 
 Positive 1005.00  
 
 
Further biological characterisation was carried out to determine the impact of the 
antagonism of the receptor in signalling processes and the use of the receptor for viral cell 
entry. Prevention of signal transduction by the natural ligand is a useful indicator of cellular 
targeting and would inhibit activation of cell recruitment. Signal inhibition was validated by 
measurement of the intracellular calcium concentration increase, which is a downstream 
effect of CXCR4 receptor activation by its specific chemokine ligand CXCL12.26 AMD3100 
and the copper(II) complex of AMD3100 were included as controls, see Table 1. The anti-
HIV assay was used to co-validate the signalling data, as this is a well-established assay, 
which provides further information on the antagonist characteristics. The anti-HIV-1 (X4 
HIV-1 NL4.3) activity of these compounds was determined in CD4+CXCR4+ human T cells 
using the well-documented HIV-1 infection assay (see Table 2).27 
Table 2 Anti-HIV X4 activity and inhibition of CXCL12-induced calcium signalling (in μM)  
Compound Anti-HIV-1 (EC50)a Ca2+ flux CXCR4 (IC50)b 
a EC50 is the effective concentration (in μM) to reduce the cytopathic effect of the CXCR4-using (X4) HIV-1 
strain NL4.3 by 50% in MT-4 cells. b IC50 is the inhibitory concentration of the compound (in μM) required to 
inhibit 50% of the CXCL-12 (SDF-1) induced Ca2+ signalling in the CXCR4-transfected U87 cell line.  
AMD3100 0.011 0.120 
Cu2AMD3100 0.062 0.113 
5  0.150 0.340 
6  0.295 0.929 
7  0.710 1.20 
Compound Anti-HIV-1 (EC50)a Ca2+ flux CXCR4 (IC50)b 
8  0.095 0.016 
10  0.845 — 
11  4.50 — 
12  0.800 — 
 
 
As already mentioned, the chelator units would be expected to interact with aspartate 
residues on the CXCR4 chemokine receptor surface via H-bonding and electrostatic 
interactions and the metal complexes would form coordinate bonds.22 In the signalling assay 
we can compare compounds 5 and 7 showing in this case that the coordination of nickel(II) 
does not increase the affinity of our compounds for CXCR4 as was observed for the same 
compounds in the flow cytometry study. This result correlates with the anti-HIV infection 
assay although both still demonstrate sub-μM values. Compounds 6 and 8 show increased 
potency of the nickel(II) complex in both calcium signalling and antiviral assays, which is 
consistent with antibody competition assay. With an IC50 of 16 nM, 8 presents a higher 
potency, compared to both AMD3100 and its copper(II) complex which both have IC50 values 
>100 nM. The presence of the appended amino group may be responsible for this bonding 
impact as it will be an effective hydrogen bond donor for interaction with the 
aspartate/glutamate rich surface of the CXCR4 receptor. 
Overall, although the AMD3100 type structure has been modified by the introduction of 
functional groups on the phenyl moiety, compounds 6 and 8 can be considered as highly 
effective CXCR4 antagonists and we can now consider the introduction of a probe 
component for molecular imaging into these structures. 
Towards molecular imaging: introduction of an imaging probe 
component 
Efficient syntheses towards functionalised AMD3100 were developed whilst maintaining 
strong anti-HIV potency and CXCR4 affinity. Both amine analogues 6 and 8 can be used to 
conjugate the AMD3100 moiety to an imaging probe as the primary amine enables coupling 
reactions with carboxylic acid, active ester or anhydride. Two different imaging probe 
components were attached, a fluorescent moiety and a PET isotope radiolabelling precursor. 
The main advantage for PET imaging here is to introduce the radiolabelling site by 
AMD3100 functionalisation rather than using the cyclam cavity to chelate a radiometal as it 
has already been described and shows low in vivo stability.17 Cyclam can form complexes that 
are thermodynamically stable in vitro but it has been shown that transchelation of the 
radiometal to ceruloplasmin and ultimately superoxide dismutase (SOD) can occur in vivo in 
the case of 64Cu,28 resulting in accumulation of the radioisotope in the blood and liver.17c  
Introduction of a BODIPY dye 
Amongst the options for fluorescent imaging components, borodipyrromethane type dyes 
(4,4-difluoro-4-borata-3a-azonia-4a-aza-s-indacene, abbreviation BODIPY®) exhibit high 
stability, high extinction coefficients, sharp emission bands and high quantum yields.29 
Additionally, BODIPYs emission can be shifted to the red-NIR region by extending the π-
conjugation of the central core30 and water soluble dyes can be obtained by addition of 
sulfonic acid moieties31 or coupling to an azamacrocycle.32 With all of these attractive 
properties, BODIPYs appear to be an excellent choice as an optical imaging component and a 
BODIPY carrying an activated ester was prepared to couple to the amine AMD3100 
analogue 6.  
Starting from BODIPY-acid, the corresponding N-hydroxysuccinimidyl ester was 
obtained upon reaction with NHS in the presence of EDCI in dichloromethane at room 
temperature in 70% yield (Scheme 5).33 The subsequent coupling of the activated ester with 6 
yields 10 in a 65% yield after purification by column chromatography. Compound 10 was 
labelled with Ni2+ and Zn2+ by adding two equivalents of appropriate metal salts. It has to be 
noted that, in this case, the zinc complex was also synthesised, in order to study the influence 
of the metal on the fluorescence of the compound. Moreover, Zn2+ also strongly increases the 
affinity of AMD3100 for the CXCR4 receptor.22 Both complexes 11 and 12 were isolated in 
almost quantitative yield. One important point is that these BODIPY-AMD3100 analogues 
are water-soluble without the requirement for any solubilising agent (such as DMSO), which 
is crucial for biological applications such as molecular imaging. Indeed, one main drawback 
for the use of BODIPY dyes in medical imaging is their very poor solubility in water. It is 
still currently challenging to introduce, in a simple synthetic manner, solubilising groups for 
biological applications. 
 
  
Scheme 5 Synthesis of Bodipy-AMD3100 
analogues.  
Anti-HIV assays were carried out with compounds 10, 11 and 12. These experiments 
showed that the introduction of the fluorescent probe induced a reduction of the anti-HIV 
activity, although 10 and 12 still maintained sub-μM activity levels, see Table 2. It was 
interesting to note that the nickel(II) complex (11) was again less active than the metal-free 
chelator 10. This suggests that the geometric preferences of the nickel(II) ion on binding to 
CXCR4 protein aspartate/glutamate side chains may be disrupted by functionalisation of the 
central phenyl ring. Zinc(II) is d10 and is more flexible in its coordination geometry. This may 
account for the higher activity of 12 compared to 11, which is more similar to the metal-free 
chelating unit 10. 
The photophysical properties of the different BODIPY-AMD derivatives were studied in 
PBS at room temperature. The data are collected in Table 3. All compounds exhibit two 
absorption bands characteristic of the BODIPY signature, which consists of the S0–S1 feature 
placed near 525 nm and the S0–S2 one located near 380 nm, both readily assigned to spin-
allowed π–π* transitions. It is important to note that no aggregation can be observed in PBS, 
which is mainly characterised by a broadening of the absorption band as well as a dual 
absorption. The ε (λ) values of the Ni(II) and Zn(II)-AMD3100-BODIPY 11 and 12, are 
relatively high, ranging from 30 200 to 53 900 M−1 cm−1, those of free ligand 10 is a little 
lower (16 500 M−1 cm−1). 
Table 3 Photophysical properties of the BODIPY derivatives in PBS at 298 K  
Compound λ abs (nm) λ em (nm) ε (M−1 cm−1) Φ  Brightnessb (M−1 cm−1) 
a The quantum yields, ΦF, were measured at 298 K, using rhodamine 6G (ΦF = 0.78 in water, λexc = 488 nm). b 
Brightness = Φ × ε.  
10  525 539 16 452 5 822 
11  524 540 53 872 7 3771 
12  524 540 30 167 27 8145 
 
 
As an example, Fig. 3 exhibits the absorption, emission and excitation spectra of 
compound 12 (see ESI† for all spectra). The ΦF value of the AMD3100-BODIPY 10 is 
relatively low, mainly because of the presence of several amine functions and a flexible 
linker between the BODIPY and the AMD3100 part (“loose bold effect”). Complexation of 
the Bodipy-AMD3100 analogue with Zn2+ (which naturally occurs when injecting AMD3100 
in vivo), resulted in a consequent enhancement of the fluorescence, yielding to a quantum 
yield of 27% and a brightness of 8200 M−1 cm−1, which is sufficient for at least in vitro 
fluorescence imaging.34 Concerning the nickel complex 11, the fluorescence is still relatively 
low (Φ = 7%). Further investigations would be needed to explain this phenomena, which may 
be due to a paramagnetic character of NiII. Nevertheless, the brightness of the compound 
(almost 4000 M−1 cm−1) is sufficient for biological applications. 
 
  
Fig. 3 Absorption (plain line), emission (large 
dashed line) and excitation (small dashed line) 
spectra of compound 11. 
 
Introduction of a precursor for radiofluorination 
Fluorine-18 has gained prominence in PET imaging in the last decades due to its widespread 
availability, relatively low cost of production and its optimal nuclear and chemical properties, 
i.e. low positron energy (635 keV), high abundance, and relatively long half-life (109.7 min) 
when compared to 11C.35 Nevertheless with a half-life of 109.7 min, the synthesis of labelled 
imaging agents needs to be rapid and efficient. The B–F bond is one of the strongest bonds 
known, Ting et al. developed a pinacol phenylboronate diester able to react with F− in a 
single, rapid and high-yielding step at pH 4–7 in aqueous solvents and at temperatures that 
are unlikely to denature biomolecules.36 Inspired by this work, the pinacol phenylboronate 
diester PET precursor was coupled to the functionalised compounds 6 and 8 (Scheme 6).  
  
Scheme 6 Synthesis of AMD3100 pinacol 
phenyl boronate analogues as PET precursors 
and AMD3100 trifluoroborate. 
 
Starting from a commercially available product, 4-(4,4,5,5-tetramethyl-1,3-2-
dioxaborolan-2-yl)benzoic acid, an activated ester 13 of the pinacol phenylboronate diester is 
synthesised by reaction with N,N′-disuccinimidyl carbonate and triethylamine in a 56% yield. 
Nucleophilic attack of 6 and 8 gives the resulting AMD3100 analogues 14 and 15 that 
constitute two precursors for 18F radiolabelling. It has to be noted that 15 was synthesised 
starting from compound 8 and not by metallation of 14, because the pinacol boronate 
intermediate was subject to hydrolysis during the metallation step. 
Fluoride treatment was performed on 14 to validate our concept. Following a previous 
reported protocol,3514 was dissolved in a small volume of deuterated methanol and an 
aqueous solution of KHF2 (3.3 eq.) was added. The solution turned immediately cloudy and 
further deuterated methanol was added to dilute the solution. The reaction mixture was stirred 
for 30 min at room temperature and the reaction was followed by 11B and 19F NMR. The 11B 
signal was shifted from 31.6 ppm to 0.4 ppm and appeared as a quadruplet due to the 
coupling between boron and fluorine. In the 19F NMR, the consumption of KHF2 was 
evidenced by the disappearance of the signal at −170 ppm and the presence of a signal at 
−142.7 ppm, characteristic of a –BF3. Fluorination was also confirmed by mass spectrometry. 
This experiment confirms the high reactivity of the pinacol phenylboronate derivatives and 
their potential as precursors for the synthesis of 18F radiopharmaceuticals. 
Conclusion 
A series of novel CXCR4 antagonists have been synthesised in this work and it has been 
demonstrated that functionalisation of the central bridging phenyl group in AMD3100 can be 
carried out without significant loss in the affinity for the CXCR4 receptor. The compounds 
have been characterised as sub-μM antagonists in a series of assays demonstrating effective 
binding to the receptor in vitro. They have then been modified for imaging applications via 
addition of a prosthetic group for radiofluorination or a fluorescent dye molecule to delineate 
the route to application. This design separates out the targeting and imaging components of 
the molecule, which is in contrast to the previously described complexes of AMD3100 with 
radiometals. The modular approach is advantageous in tuning for different modalities and 
optimum receptor ‘on’ and ‘off’ binding rates. There is also the potential for multimodal 
imaging to allow evaluation of the compounds by a range of imaging techniques to more 
precisely characterise the interactions from a cellular level up to in vivo studies. The next 
steps for this study are to select the optimal candidates, optimise the radiolabelling conditions 
and carry out preliminary in vivo studies. In addition, the affinity towards CXCR7 of the 
novel compounds is under evaluation to determine the binding profile with this important and 
related chemokine receptor target.  
Experimental section 
Synthetic procedures 
General information. Additional experimental details, data for compounds 1–16 (NMR, 
MS spectra and HPLC chromatograms) are given in ESI.†  
Material. TriBocCyclam was generously donated by CheMatech and all other chemicals 
were purchased from Acros and Aldrich and were used without further purification. Organic 
solvents were removed under reduced pressure using rotary evaporator. Water was removed 
by lyophilisation.  
Methyl-2,5-dimethylbenzoate (1). A mixture of 2,5-dimethylbenzoic acid (10.0 g, 66.6 
mmol), sulphuric acid (14 mL, 13.3 mmol), and methanol (27 mL) was heated at reflux for 4 
h. The mixture was poured into water (250 mL) and extracted with ethyl acetate (2 × 200 
mL). The pooled organics were washed with saturated sodium bicarbonate (2 × 50 mL) and 
brine (50 mL), dried over MgSO4, and concentrated in vacuo to give 1 (10.1 g, 92%) as a 
colorless oil. 1H NMR (300 MHz, CDCl3, 300 K): δ = 7.70 (d, 4J (H,H) = 1.7 Hz, 1H; CH), 
7.18 (dd, 3J (H,H) = 7.9 Hz, 4J (H,H) = 1.4 Hz, 1H; CH), 7.10 (d, 3J (H,H) = 7.9 Hz, 1H; CH), 
3.86 (s, 3H; OCH3), 2.53 (s, 3H; CH3), 2.32 ppm (s, 3H; CH3); 13C{1H} NMR (75 MHz, 
CDCl3, 300 K): δ = 168.4 (C O), 137.2 (Car), 135.4 (Car), 132.9 (CHar), 131.8 (CHar), 
131.2 (CHar), 129.6 (Car), 51.9 (OCH3), 21.4 (CH3), 20.9 ppm (CH3); ESI-MS: m/z: 165.31 
[M + H]+.  
Methyl-2,5-bis(bromomethyl)benzoate (2). To a solution of 1 (10.1 g, 61.6 mmol) in 
carbon tetrachloride (300 mL) were added N-bromosuccinimide (23.0 g, 129.3 mmol) and 
benzoyl peroxide (1.0 g, 4.1 mmol). The reaction mixture was heated at reflux for 4 h. The 
resulting suspension was filtered, and the residue was washed with chloroform (3 × 150 mL). 
The pooled organics were concentrated in vacuo to give a mixture of product and succinimide 
as determined by 1H NMR. The mixture was dissolved in dichloromethane (600 mL) and 
washed with water (3 × 150 mL). The dichloromethane phase was dried over MgSO4 and 
concentrated in vacuo, and the resulting residue was purified by reverse phase flash 
chromatography on C18. After evaporation of acetonitrile, the aqueous solution was freeze 
dried to give 2 (13.9 g, 70%) as a white solid. 1H NMR (500 MHz, CDCl3, 300 K): δ = 8.00 
(d, 4J (H,H) = 1.8 Hz, 1H; CH), 7.53 (dd, 3J (H,H) = 7.8 Hz, 4J (H,H) = 1.8 Hz, 1H; CH), 7.46 
(d, 3J (H,H) = 7.8 Hz, 1H; CH), 4.94 (s, 2H; CH2), 4.49 (s, 2H; CH2), 3.98 ppm (s, 3H; 
OCH3); 13C{1H} NMR (75 MHz, CDCl3, 300 K): δ = 166.6 (C O), 139.6 (Car), 138.5, 133.2 
(CHar), 132.5, 132.0, 129.7 (Car), 52.6 (OCH3), 32.0 (CH2), 31.0 ppm; ESI-MS: m/z: 322.54 
[M + H]+.  
AMD3100 Boc-ester (3). To a solution of tris-tert-butyl-1,4,8,11-tetraazacyclotetradecane-
1,4,8-tricarboxylate (2.00 g, 3.98 mmol) in acetonitrile (20 mL) was added K2CO3 (1.38 g, 
9.99 mmol) and compound 2 (0.63 g, 1.99 mmol). The reaction mixture was heated at 40 °C 
overnight. After cooling, the solution was filtered on celite. The solvent was evaporated and 
the resulting oil was taken up in 200 mL of diethylether, washed with 2 × 50 mL of water, 
dried over MgSO4 and concentrated in vacuo. The resulting residue was purified by flash 
chromatography (A: CH2Cl2, B: CH3OH, B 35%) to give 3 (1.89 g, 82%) as a white foam. 
m.p. 89 ± 1 °C; 1H NMR (300 MHz, CDCl3, 300 K): δ = 7.66 (s, 1H; CH), 7.43 (d, 3J (H,H) = 
7.7 Hz, 1H; CH), 7.31 (d, 3J (H,H) = 7.7 Hz, 1H, CH), 3.85 (s, 3H; OCH3), 3.81 (s, 2H; 
CH2Ph), 3.51 (s, 2H; CH2Ph), 3.45–3.14 (m, 23H), 2.67–2.52 (m, 4H), 2.45–2.28 (m, 4H), 
1.94–1.77 (m, 4H; CH2β), 1.70–1.61 (m, 4H; CH2β), 1.50–1.24 ppm (m, 54H; CH3); 13C{1H} 
NMR (125 MHz, DMSO, 343 K): δ = 167.4 (C O), 154.5 (*2), 154.4, 154.3 (*2), 154.2, 
138.1 (Car), 137.5 (Car), 131.3 (Car), 130.3 (CHar), 129.7 (CHar), 129.6 (CHar), 78.4, 78.3, 
78.2, 78.1, 78.0 (*2), 57.8, 56.2, 52.7, 52.5, 51.3, 51.1, 46.7, 46.6, 46.5(*3), 46.2, 46.0, 45.9 
(*2), 45.8, 45.7, 45.5, 45.4, 27.8 (*12) (CH3), 27.7 (*3) (CH3), 27.6 (*3) (CH3), 25.9 (*2) 
(CH2β), 25.6 pm (*2) (CH2β); ESI-MS: m/z: 1183.76 [M + Na]+, 1199.73 [M + K]+; HRMS 
(ESI): m/z calcd for C60H104N8O14 + Na+: 1183.7571, found 1183.7564; elemental analysis 
calcd (%) for C60H104N8O14: C 62.04, H 9.02, N 9.65; found: C 61.62, H 8.98, N 9.55; HPLC: 
tr = 8.13 min, purity 98%.  
AMD3100 Boc-ethylenediamine (4). Compound 3 (1.89 g, 1.63 mmol) was dissolved in 
distilled ethylenediamine (6.5 mL). The mixture was stirred at 40 °C for 7 days. The mixture 
was concentrated by evaporation and the resulting oil was taken up in acetone (200 mL). 
After filtration, the pooled organics were concentrated in vacuo to give a yellow foam. The 
resulting residue was purified by flash chromatography on silica gel (A: CH2Cl2, B: CH3OH, 
B 15%) to furnish 4 (0.77 g, 40%) as a white foam. m.p. 98 ± 1 °C; 1H NMR (500 MHz, 
CDCl3, 324 K): δ = 8.17 (br.s, 1H; NHC O), 7.49 (s, 1H; CH), 7.25 (d, 3J (H,H) = 7.3 Hz, 
1H; CH), 7.20 (d, 3J (H,H) = 7.6 Hz, 1H; CH), 3.64 (s, 2H, CH2Ph), 3.50 (s, 2H, CH2Ph), 3.46 
(q, 3J (H,H) = 6.0 Hz, 2H; CH2NHC O), 3.40–3.16 (m, 24H), 2.93 (t, 3J (H,H) = 6.0 Hz, 2H; 
CH2NH2), 2.66 (t, 3J (H,H) = 6.5 Hz, 2H), 2.60–2.52 (m, 2H), 2.46 (t, 3J (H,H) = 6.5 Hz, 2H), 
2.40 (t, 3J (H,H) = 5.7 Hz, 2H), 2.10 (s, 2H), 1.89–1.77 (m, 4H; CH2β), 1.71–1.61 (m, 4H; 
CH2β), 1.44–1.39 (m, 36H; CH3), 1.37–1.24 ppm (m, 18H; CH3); 13C{1H} NMR (125 MHz, 
CDCl3, 324 K): δ = 169.9 (C O), 156.1, 156.0, 155.9 (*2), 155.7 (*2), 138.7 (Car), 137.4 
(Car), 135.1 (Car), 131.2 (CHar), 130.5 (CHar), 129.3 (CHar), 80.0, 79.9 (*2), 79.8 (*2), 79.7, 
59.6 (CH2), 58.0, 53.5, 52.5, 52.4, 52.1, 51.1, 50.9, 48.1 (*2), 48.0, 47.5, 47.3 (*2), 46.9, 
46.5, 43.1 (*2), 42.1 (*2), 28.9 (*3) (CH3), 28.8 (*9) (CH3), 28.7 (*3) (CH3), 28.6 (*3) (CH3), 
27.2 (*2) (CH2β), 26.1 ppm (*2) (CH2β); ESI-MS: m/z: 1189.82 [M + H]+; HRMS (ESI): m/z 
calcd for C61H108N10O13 + H+: 1189.8170, found 1189.8212; elemental analysis calcd (%) for 
C61H108N10O13: C 61.59, H 9.15, N 11.77; found C 61.17, H 9.43, N 11.51; HPLC: tr = 8.48 
min, purity 96%.  
AMD3100-ester (5). A solution of 3 M HCl (3.0 mL) was added to 3 (100.0 mg, 0.08 mmol) 
and the reaction mixture was stirred for one hour. The resulting product was left one night at 
room temperature. The acid was evaporated in vacuo giving 5 + 6HCl +10H2O. (60.7 mg, 
yield = 73%) as a white foam. 1H NMR (300 MHz, D2O, 300 K): δ = 8.32 (d, 4J (H,H) = 1.8 
Hz, 1H), 7.88 (dd, 3J (H,H) = 7.8 Hz, 4J (H,H) = 1.8 Hz, 1H), 7.76 (d, 3J (H,H) = 7.8 Hz, 1H), 
4.46 (br.s, 2H), 3.98 (s, 3H; OMe), 3.92–3.81 (m, 2H), 3.76–3.53 (m, 17H), 3.49–3.28 (m, 
15H), 2.29–2.12 ppm (m, 8H); 13C{1H} NMR (75 MHz, D2O, 300 K): δ = 168.1, 135.9, 
134.9, 134.2, 133.4, 131.2, 131.0, 48.2, 47.9, 45.5, 44.8, 42.1, 41.6, 41.5, 40.8, 40.7, 38.44, 
38.38, 38.0, 37.2, 36.8, 19.1 (CH2β), 19.0, 18.5, 17.9 ppm; HRMS (ESI): m/z calcd for 
C30H56N8O2 + H+: 561.4599, found 561.4573; elemental analysis calcd (%) for C30H56N8O2 + 
10H2O + 6HCl: C 37.54, H 8.61, N 11.68; found C 37.82, H 8.05, N 11.65; HPLC: tr = 5.53 
min, purity 97%.  
AMD3100-ethylenediamine (6). Compound 4 (0.47 g, 0.40 mmol) was dissolved in a 
solution of 3 M HCl (10 mL). The mixture was stirred overnight at room temperature. The 
mixture was evaporated, taken up in acetone (50 mL) and then stirred overnight. The 
precipitate was filtered, washed with acetone and ether and finally dried in vacuo. The 
compound 6 + 9HCl + 5H2O was obtained as a white solid (400 mg, yield = 100%). 1H NMR 
(300 MHz, D2O, 300 K): δ = 7.93–7.91 (s, 1H), 7.81–7.74 (m, 2H), 4.51 (s, 2H; CH2Ph), 4.29 
(s, 2H; CH2Ph), 3.82–3.78 (m, 2H), 3.67–3.34 (m, 32H), 3.18–3.14 (m, 2H), 2.27–2.16 ppm 
(m, 8H; CH2β); 13C{1H} NMR (75 MHz, D2O, 300 K): δ = 171.0 (C O), 135.7 (CHar), 134.5 
(CHar), 134.4 (CHar), 133.4 (Car), 131.6 (Car), 130.2 (Car), 58.1, 57.5, 48.4, 47.9, 47.8, 
45.6, 45.3, 45.0, 42.1, 41.8, 41.7, 41.2, 41.0, 38.9, 38.7, 38.5, 38.1, 37.8, 37.7, 37.6, 19.3 
(CH2β), 19.2 (CH2β), 18.8 (CH2β), 18.5 ppm (CH2β); HRMS (ESI): m/z calcd for C31H60N10O 
+ H+: 589.5024, found 589.5034; elemental analysis calcd (%) for C31H61N10O + 9HCl + 
5H2O: C 36.97, H 7.91, N 13.91; found C 37.13, H 8.06, N 14.33.  
Few drops of NaOH (16 mol L−1) were added on compound 6 + 9HCl + 5H2O in order to 
obtain a viscous solution and chloroform (100 mL) was added quickly. The two layers were 
separated and the organic layer was dried over magnesium sulfate. After evaporation of the 
solvent, 6 + 9.5H2O (276 mg, yield = 91%) was obtained as a light yellow oil. 1H NMR (300 
MHz, CDCl3, 300 K): δ = 8.64 (t, 3J (H,H) = 5.4 Hz, 1H; NHC O), 7.41 (d, 3J (H,H) = 7.8 
Hz, 1H), 7.37 (d, 4J (H,H) = 1.7 Hz, 1H), 7.12 (dd, 3J (H,H) = 7.8 Hz, 4J (H,H) = 1.7 Hz, 1H), 
3.51 (s, 2H; CH2Ph), 3.37 (s, 2H; CH2Ph), 3.32 (q, 3J (H,H) = 5.9 Hz, 2H; CH2NHC O), 2.76 
(t, 3J (H,H) = 6.2 Hz, 2H; CH2NH2), 2.71–2.19 (m, 40H), 1.72 (quint, 3J (H,H) = 5.5 Hz, 2H; 
CH2β), 1.63 (quint, 3J (H,H) = 5.5 Hz, 2H; CH2β), 1.55–1.45 ppm (m, 4H; CH2β); 13C{1H} 
NMR (75 MHz, D2O, 300 K): δ = 170.5 (C O), 137.9 (Car), 137.6 (Car), 135.7 (Car), 130.6 
(CHar), 130.4 (CHar), 128.0 (CHar), 57.9 (CH2Ph), 55.8 (CH2Ph), 54.6, 54.2, 53.3, 53.2, 
50.9, 50.5, 49.3, 49.1, 48.7, 48.6, 48.5, 48.3, 48.2, 47.8, 47.7, 47.3, 43.1, 41.9, 28.6 (CH2β), 
28.4 (CH2β), 26.5 (CH2β), 26.1 ppm (CH2β); elemental analysis calcd (%) for C31H61N10O + 
9.5H2O: C 48.99, H 10.48, N 18.43; found C 49.00, H 10.57, N 18.33; HPLC: tr = 5.36 min, 
purity 99%. 
Ni2AMD3100-ester (7). 0.60 mL (0.06 mmol) of a titrated solution of Ni(NO3)2, 6H2O (c = 
0.106 mol L−1) in water were added to a solution of 5 (17.3 mg, 0.03 mmol) in a 3 mL 
mixture of MeOH–H2O (9 : 1). The reaction was stirred at 50 °C overnight. After completion, 
reverse phase C8 semi-preparative HPLC (A: H2O) was performed to furnish 7 (3.7 mg, 18%) 
as a light orange foam. HRMS (ESI): m/z calcd for C30H54N8Ni2O2 − 2H2+: 337.1533, found 
337.1529; HPLC: tr = 5.88 min, purity 95%.  
Ni2AMD3100-ethylenediamine (8). 15.0 mL (1.59 mmol) of a titrated solution of Ni(NO3)2, 
6H2O (c = 0.106 mol.L−1) in water were added to a solution of 6 + 9.5H2O (568 mg, 0.79 
mmol) in a 110 mL mixture of MeOH–H2O (9 : 1). The reaction was stirred at 50 °C 
overnight. After completion, reverse phase C18 flash chromatography (A: H2O) was 
performed to furnish 8 + 4NO3 + 7H2O (332 mg, 39%) as a light orange foam. UV-Vis 
(PBS), λ (nm): 460; HRMS (ESI): m/z calcd for C31H58N10Ni2O − 2H2+: 351.1746, found 
351.1740; elemental analysis calcd (%) for C31H58N10Ni2O + 4NO3 + 9.5H2O: C 34.59, H 
6.56, N 18.22; found C 34.24, H 6.30, N 18.88; HPLC: tr = 5.77 min, purity 88%.  
Bodipy-NHS-ester (9)30. 54 mg of N-hydroxysuccinimide (0.48 mmol), 58 mg of 
dimethylaminopyridine (DMAP) (0.48 mmol) and 92 mg of 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDCI) (0.48 mmol) were added to a solution of 4,4-
difluoro-8-(4-carboxyphenyl-)1,3,5,7-tetramethyl-2,6-diethyl-4-bora-3a,4a-diaza-s-indacene 
(100 mg, 0.24 mmol) in CH2Cl2 (50 mL). The reaction was stirred at 35 °C. After complete 
activation of the acid function (2 h) followed by TLC, the mixture was washed with 2 × 10 
mL of water, the organic phase was dried over MgSO4 and the solvent was evaporated to give 
a red oil. The crude product was purified by chromatography on silica gel (AcOEt–Hexane 
50 : 50). Upon concentration of the pure fraction, recrystallisation in a mixture of 
dichloromethane and hexane gave 9 as a red solid (88 mg, yield = 70%). 1H NMR (300 MHz, 
CDCl3, 300 K): δ = 8.23 (d, 3J (H,H) = 8.3 Hz, 2H; CHarBod), 7.47 (d, 3J (H,H) = 8.3 Hz, 2H; 
CHarBod), 2.92 (bs, 4H; CH2C O), 2.51 (s, 6H; CH3), 2.27 (q, 3J (H,H) = 7.5 Hz, 4H; 
CH2CH3), 1.25 (s, 6H; CH3), 0.96 ppm (t, 6H, 3J (H,H) = 7.5 Hz; CH2CH3); 13C{1H} NMR (75 
MHz, CDCl3, 300 K): δ = 169.2 (*2) (NC O), 161.4 (CO2), 154.6 (*2) (Cpyrrole), 143.0 
(CarBod), 138.7 (CBod), 138.0 (*2) (Cpyrrole), 137.7 (*2) (Cpyrrole), 133.3 (*2) (CHarBod), 131.2 (*2) 
(Cpyrrole), 129.3 (*2) (CHarBod), 125.6 (CarBod), 25.7 (*2) (CH2C O), 17.3 (*2) (CH2CH3), 14.6 
(*2) (CH2CH3), 12.7 (*2) (CH3), 12.1 ppm (*2); 11B{1H} NMR (192.5 MHz, CDCl3, 300 K): δ 
= 0.79 ppm (t, 1J (B,F) = 33.1 Hz); ESI-MS: m/z = 544.21 [M + Na]+; UV-Vis (CH3CN), λ 
(nm) (ε, M−1 cm−1): 525 (73 000), 492 (sh, 23 200), 378 (7940); elemental analysis calcd (%) 
for C28H30BF2N3O4: C 68.50, H 6.67, N 6.39; found C 68.78, H 6.87, N 5.95.  
AMD3100-bodipy (10). Diisopropylethylamine (172 μL, 1.04 mmol) was added to a 
solution of 6 (408 mg, 0.69 mmol) in acetonitrile (40 mL). A solution of bodipy 9 (694 mg, 
0.69 mmol) in acetonitrile (10 mL) was then added and the mixture was stirred at room 
temperature during 6 h, until total consumption of the starting materials was observed by 
TLC. Solvent was evaporated, and the resulting red oil was purified by column 
chromatography on silica gel (eluent: CH2Cl2–EtOH–NH4OH 20 : 60 : 20). Precipitation from 
CH2Cl2–hexane gave the desired compound 10 as a red solid (446 mg, yield = 65%) Mp: 
>200 °C; 1H NMR (300 MHz, CDCl3, 300 K): δ = 9.80–9.67 (bs, 1H), 8.62–8.49 (bs, 1H), 
8.12 (d, 3J (H,H) = 8.2 Hz, 2H), 7.55 (d, 3J (H,H) = 7.7 Hz, 1H), 7.43 (s, 1H), 7.33 (d, 3J 
(H,H) = 8.2 Hz, 2H), 7.20 (d, 3J (H,H) = 7.7 Hz, 1H), 3.73–3.46 (m, 12H), 2.79–2.31 (m, 
37H), 2.26 (q, 4H, 3J (H,H) = 7.5 Hz; CH2CH3), 1.92–1.52 (m, 8H), 1.32–1.24 (m, 9H), 0.94 
ppm (t, 3J (H,H) = 7.5 Hz, 6H; CH2CH3); 13C{1H} NMR (75 MHz, CDCl3, 300 K): δ = 173.0 
(NHC O), 166.6, 154.3 (*2) (Cpyrrole), 139.8 (Car), 139.3 (CarBod), 139.2 (CBod), 138.3 (*2) 
(Cpyrrole), 138.2 (Car), 136.1, 134.5 (CarBod), 133.2 (*2) (Cpyrrole), 131.5 (CHar), 130.6 (*2) 
(Cpyrrole), 130.5 (CHar), 128.8 (*2) (CHarBod), 128.3 (*2), 127.2 (CHar), 58.3 (CH2), 55.2, 54.9, 
54.6, 54.2, 53.8, 53.2, 51.3, 51.1, 49.9, 49.4 (*2), 48.8, 48.6, 48.5, 48.4, 48.1, 47.1, 42.8, 
39.7, 28.7 (CH2β), 28.6, 26.6, 26.2, 17.2 (*2) (CH2CH3), 14.8 (*2) (CH2CH3), 12.7 (*2) 
(CH3), 12.0 ppm (*2); 11B{1H} NMR (96 MHz, CDCl3, 300 K): δ = 0.76 ppm (t, 1J (B,F) = 
33.6 Hz); ESI-MS: m/z = 995.7 [M + H]+, 1021.7 [M + Na]+, 1033.7 [M + K]+; HRMS (ESI): 
m/z calcd for C55H85BF2N12O2 + H+: 995.7062, found 995.7012.  
Ni2AMD3100-bodipy (11). 3.1 mg of NiCl2 (0.023 mmol) was added to a solution of 10.4 
mg of compound 10 (0.012 mmol) in 6 mL of methanol. The mixture was stirred at 50 °C for 
2 h. After evaporation, compound 11 was obtained as a red solid (14.2 mg, yield = 95%). 
ESI-MS: m/z = 555.27 [M − 2H − 4Cl]2+; HRMS (ESI): m/z calcd for C55H85BCl4F2N12Ni2O2 − 
2H − 4Cl2+: 555.2740, found 555.2699.  
Zn2AMD3100-bodipy (12). 4.7 mg of Zn(OAc)2, 2H2O (0.021 mmol) was added to a 
solution of 9.5 mg of compound 10 (0.011 mmol) in 6 mL of methanol. The mixture was 
stirred at 50 °C for 2 h. After evaporation, compound 12 was obtained as a red solid (27.7 
mg, yield = 97%). ESI-MS: m/z = 592.28 [M − H − 3(OAc)]2+; HRMS (ESI): m/z calcd for 
C63H97BF2N12O10Zn2 − H − 3(OAc)2+: 592.2783, found 592.2780.  
Pinacol phenylboronate activate ester (13). Triethylamine (340 μL, 2.43 mmol) and 
N,N′-disuccinimidyl carbonate (310 mg, 1.21 mmol) were added to a solution of 4-(4,4,5,5-
tetramethyl-1,3-2-dioxaborolan-2-yl)benzoic acid (200 mg, 0.81 mmol) in acetonitrile (20 
mL). The reaction mixture was stirred at room temperature for 5 h. The solvent was 
evaporated in vacuo with a bath temperature lower than 35 °C. The resulting product was 
dissolved in dichloromethane and washed with a saturated solution of sodium bicarbonate. 
After drying over magnesium sulfate, the organic layer was evaporated in vacuo with a low 
temperature bath >35 °C. Chromatography on silica gel (A: Pentane, B: EtOAc, B 50%) gave 
13 (0.157 g, 56%) as a white powder. 1H NMR (300 MHz, CDCl3, 300 K): δ = 8.09 (d, 3J 
(H,H) = 8.1 Hz, 2H; CHarBpinacol), 7.90 (d, 3J (H,H) = 8.1 Hz, 2H; CHarNHS), 2.86 (s, 4H; CH2 
NHS), 1.33 ppm (s, 12H; CH3); 13C{1H} NMR (75 MHz, CDCl3, 300 K): δ = 169.4 (*2) (CC
O NHS), 162.1 (CC O), 135.1 (Cpinacol), 129.6 (*4) (CH), 127.3 (CNHS), 84.6 (*2) (CMe2), 
25.9 (*2) (CH2), 25.0 ppm (*4) (CH3); HRMS (ESI): m/z calcd for C17H20BNO6 + Na+: 
368.1279, found 368.1274.  
AMD3100-pinacol phenylboronate (14). 6 (26 mg, 0.04 mmol) was dissolved in a 
mixture of acetonitrile (600 μL) and DMF (20 μL), triethylamine (77 μL) was then added. 
The solution was stirred at room temperature for 10 min and 13 (15 mg, 0.04 mmol) was 
added to the reaction. After one night stirring at 40 °C, the solvent was evaporated under a 
nitrogen flux to give 14 which still contains traces of DMF and was directly used without any 
further purification step. 1H NMR (500 MHz, CDCl3, 500 K): δ = 9.79–9.63 (bs, 1H; NH), 
8.77–8.65 (bs, 1H; NH), 8.07 (dd, 3J (H,H) = 5.2 Hz, 4J (H,H) = 1.5 Hz, 2H), 7.75 (d, 3J 
(H,H) = 8.1 Hz, 1H), 7.72–7.65 (m, 1H), 7.63 (d, 3J (H,H) = 8.1 Hz, 1H), 6.63 (dd, 3J (H,H) = 
5.1 Hz, 4J (H,H) = 1.5 Hz, 2H), 3.70–3.31 (m, 7H), 2.90–2.85 (m, 7H), 2.73–2.20 (m, 35H), 
1.79–1.52 (m, 6H), 1.19 ppm (s, 12H); 11B (160 MHz, CDCl3, 300 K): δ = 31.6 ppm; ESI-
MS: m/z = 819.6 [M + H]+; MALDI-TOF: m/z = 819.63 [M + H]+.  
Ni2AMD3100-pinacol phenylboronate (15). 8 (20 mg, 0.02 mmol) was dissolved in DMF 
(3 mL) and triethylamine (25 μL) was added. The solution was stirred at room temperature 
for 10 min and 13 (8 mg, 0.02 mmol) was added to the reaction. After one night stirring at 40 
°C, the solvent was evaporated in vacuo with a bath temperature lower than 35 °C to give 15. 
MALDI-TOF: m/z = 931.36 [M − 3H]+.  
AMD3100-phenyltrifluoroboronate (16). 14 (0.04 mmol) was dissolved in methanol-d4 
(150 μL) and a solution of KHF2 in D2O (35 μL, c = 4 M) was added. The solution 
immediately turned blurry and 1 mL of methanol-d4 was added. The mixture was stirred for 
30 min and NMR was recorded on the crude product. 1H NMR (500 MHz, CD3OD, 500 K): δ 
= 8.08 (d, 3J (H,H) = 7.5 Hz, 2H), 7.72–7.69 (m, 1H), 7.61–7.57 (m, 1H), 7.44 (bs, 1H), 6.87 
(d, 3J (H,H) = 6.9 Hz, 2H), 3.80–3.61 (m, 6H), 3.23–3.15 (m, 7H), 3.14–3.03 (m, 7H), 2.99–
2.87 (m, 10H), 2.76–2.54 (m, 12H), 2.02–1.76 ppm (m, 6H); 11B (160 MHz, CD3OD, 300 K): 
δ = 0.34 ppm (q, 1J (B,F) = 11.9 Hz); 19F (202 MHz, CD3OD, 300 K): δ = −142.7 ppm; ESI-
MS: m/z = 759.5 [M − H]−.  
Chemokine-induced calcium signalling assay 
Ca2+ mobilisation assays were performed by the use of a fluorometric imaging plate reader 
(FLIPR) (Molecular Devices, Sunnyvale, USA) as described previously.26 Briefly, 
U87.CXCR4- and U87.CCR5-transfected cells were loaded with the fluorescent calcium 
indicator Fluo-3 acetoxymethyl (Molecular Probes, Leiden, The Netherlands) in the 
appropriate culture medium for 45 min at 37 °C, after which the cells were washed three 
times in Hanks balanced salt solution buffer containing 20 mM HEPES and 0.2% bovine 
serum albumin (pH 7.4). The cells were then incubated in the dark at 37 °C for 15 min with 
the compounds. Changes in intracellular calcium concentration upon addition of CXCL-12 
(SDF-1), the specific ligand for CXCR4, were simultaneously measured in all 96 wells in a 
black-wall microtiter plate and in real time with the FLIPR. The data were expressed as 
fluorescence units versus time and were analysed using the FLIPR Control Software 
(Molecular Devices) and IC50 values were calculated using GraphPad Prism 4.0 software (San 
Diego, CA).  
Anti-viral assays 
Anti-HIV activity and cytotoxicity measurements in MT-4 cells were based on the viability 
of cells that had been infected or not infected with the CXCR4-using (X4) HIV-1 strain 
NL4.3 and exposed to various concentrations of the test compound. After the MT-4 cells 
were allowed to proliferate for 5 days, the number of viable cells was quantified by a 
tetrazolium-based colorimetric method as described by Pauwels et al.27,37  
Flow cell cytometry anti-CXCR4 antibody competition studies 
Cell culture. Human leukaemia T cell lymphoblasts (Jurkat) were obtained from MRL 
(University of Hull, UK). These cells were cultured in RPMI 1640 medium treated with 
sterile filtered fetal bovine serum (FBS) (10%) and penicillin and streptomycin (100 units per 
5 mL) antibiotics. The cells cultures were maintained at 37 °C in a humidified, CO2 (5%) 
controlled atmosphere with subculturing done every 2–3 days as appropriate.  
General procedure for binding assay with 12G-5 conjugated to 
phycoerythrin 
Phycoerythrin (PE)-conjugated mouse monoclonal anti-human CXCR-4 and Mouse IgG2A 
isotype control-PE were purchased from R&D systems Europe, Abingdon, UK.  
Cells are harvested at about 75% confluency, centrifuged, resuspended in 10 mL PBS and 
centrifuged again. Cells are kept on ice to prevent receptor internalisation. Cells are 
resuspended in 1.0 mL of PBS/0.25% BSA/0.01 M NaN3 and viable cells are counted using 
trypan-blue exclusion test. Cells at a density of 1–2 × 105 cells were aliquoted into 
polypropylene FACS tubes and preincubated with 20 μM of the compound (10 μL in 18.2 
mΩ water) for one hour at 4 °C. A high concentration of compound was used to ensure 
saturation of the receptors. Thereafter, cells were washed with 1 mL of the buffer 
(PBS/0.25% BSA/0.01 M NaN3) to remove the excess of compound that did not bind to the 
cells’ receptors. Cells were then incubated with the 12G-5 mAb conjugated to phycoerythrin 
for a further 60 min. The cells were washed with 1 mL of the buffer and put in suspension in 
300 μL of the buffer. Negative control was performed using the same protocol without the 
preincubation step. The binding of our compound was analysed by flow cytometry on a 
FACScan flow cytometer (BD Biosciences Europe, Erembodegem, Belgium) using the 
following FL channel FL-2 575/26 nm (PE/PI). 
The potency of compounds is reported as a concentration required to inhibit a specified 
amount (%) of the mABs. The Mean Fluorescent Intensity (MFI) was used as a measure of 
binding and a quantitative way of calculating the inhibition percentage of mAb. 
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† Electronic supplementary information (ESI) available: Spectra and analytical data for the compounds synthesised. 
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